Pharmacodynamic (PD) responses drive dose/schedule selection of CC-92480, a novel CELMoD agent, in a phase 1 dose-escalation study in relapsed/refractory multiple myeloma (RRMM).

被引：0

作者：

Wong, Lilly

Jimenez Nunez, Maria Dolores

Bahlis, Nizar J.

Vangsted, Annette J.

Ramasamy, Karthik

Trudel, Suzanne

Martinez, Joaquin

Mateos, Maria-Victoria

Rodriguez Otero, Paula

Lonial, Sagar

Popat, Rakesh

Oriol, Albert

Karanes, Chatchada

Orlowski, Robert Z.

Berdeja, Jesus G.

Wang, Maria

Lamba, Manisha

Pourdehnad, Michael

Pierce, Daniel W.

Richardson, Paul G.

机构：

[1] Bristol Myers Squibb, San Diego, CA USA

[2] Celgene Res SLU, Seville, CA, Spain

[3] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[4] Rigshosp, Dept Haematol, Copenhagen, Denmark

[5] Oxford Univ Hosp NHS Fdn Trust, Dept Clin Haematol, Oxford, England

[6] Univ Toronto, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada

[7] Univ Complutense Madrid, Hosp Octubre 12, Dept Hematol, H120 CNIO Clin Res Unit,CIBERONC, Madrid, Spain

[8] Univ Hosp Salamanca IBSAL, Salamanca, Spain

[9] Univ Clin Navarra, Ctr Appl Med Res CIMA, IDISNA, Pamplona, Spain

[10] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[11] Univ Coll London Hosp NHS Fdn Trust, NIHR UCLH Clin Res Facil, London, England

[12] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain

[13] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Badalona, Spain

[14] City Hope Natl Med Ctr, Judy & Bernard Briskin Ctr Multiple Myeloma Res, Duarte, CA USA

[15] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[16] Sarah Cannon Ctr Blood Canc, Nashville, TN USA

[17] Bristol Myers Squibb, Summit, NJ USA

[18] Bristol Myers Squibb, San Francisco, CA USA

[19] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8531

引用

页数：2

共 50 条

[31] Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial
Orlowski, Robert Z.
Bahlis, Nizar J.
Quach, Hang
Popat, Rakesh
Lonial, Sagar
Kim, Kihyun
Mateos, Maria-Victoria
Pawlyn, Charlotte
Ramasamy, Karthik
Martinez-Lopez, Joaquin
Casas-Aviles, Ignacio
Spirli, Alessia
Gong, Jing
Amatangelo, Michael
Katz, Jessica
Maciag, Paulo
Peluso, Teresa
Richardson, Paul G.
Trudel, Suzanne
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S492 - S493
[32] Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)
Spencer, Andrew
Iversen, Katrine Fladeland
Dhakal, Binod
Creignou, Maria
Chen, Jenny
Hiemstra, Ida H.
Bosgra, Sieto
Badani, Avani
Breij, Esther C. W.
Brady, Lauren K.
Sasser, A. Kate
Malmberg, Anders
Gregersen, Henrik
Hansson, Markus
Broijl, Annemiek
Mateos, Maria-Victoria
Plesner, Torben
BLOOD, 2022, 140 : 7320 - 7321
[33] A PHASE IB DOSE-ESCALATION STUDY OF ORAL PANOBINOSTAT (LBH589) AND IV BORTEZOMIB IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
San Miguel, J.
Sezer, O.
Siegel, D.
Guenther, A.
Blade, J.
Prosser, I.
Hazell, K.
Bengoudifa, R.
Klebsattel, M.
Bourquelot, P.
Cavo, M.
Goebeler, M.
Niederweiser, D.
Milder, M.
Boccadoro, M.
Anderson, K.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 155 - 155
[34] A Phase 1 Dose-Escalation Study of Filanesib Plus Bortezomib and Dexamethasone in Patients With Recurrent/ Refractory Multiple Myeloma
Chari, Ajai
Htut, Myo
Zonder, Jeffrey A.
Fay, Joseph W.
Jakubowiak, Andrzej J.
Levy, Joan B.
Lau, Kenneth
Burt, Steven M.
Tunquist, Brian J.
Hilder, Brandi W.
Rush, Selena A.
Walker, Duncan H.
Ptaszynski, Mieke
Kaufman, Jonathan L.
CANCER, 2016, 122 (21) : 3327 - 3335
[35] A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Gonsalves, Wilson, I
Neparidze, Natalia
Allred, Jacob B.
Kumar, Shaji K.
Reid, Joel M.
Shapiro, Geoffrey
Costello, Brian A.
Piekarz, Richard
Baz, Rachid C.
Devarakonda, Srinivas
BLOOD, 2022, 140 : 7315 - 7316
[36] Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma
Shinsuke Iida
Kensei Tobinai
Masafumi Taniwaki
Yoshihisa Shumiya
Toru Nakamura
Takaaki Chou
International Journal of Hematology, 2016, 104 : 596 - 604
[37] A phase 1 dose-escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma
Kumar, Anita
Blum, Kristie A.
Fung, Henry C.
Smith, Mitchell R.
Foster, Paul A.
Younes, Anas
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (06) : 902 - 904
[38] Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma
Iida, Shinsuke
Tobinai, Kensei
Taniwaki, Masafumi
Shumiya, Yoshihisa
Nakamura, Toru
Chou, Takaaki
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 104 (05) : 596 - 604
[39] MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study
Raab, Marc S.
Chatterjee, Manik
Goldschmidt, Hartmut
Agis, Hermine
Blau, Igor
Einsele, Hermann
Engelhardt, Monika
Ferstl, Barbara
Gramatzki, Martin
Rollig, Christoph
Weisel, Katja
Jarutat, Tiantom
Weinelt, Dominika
Winderlich, Mark
Peschel, Christian
BLOOD, 2018, 132
[40] A Phase I Dose Escalation Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma
Kourelis, Taxiarchis
Ailawadhi, Sikander
Vogl, Dan T.
Cooper, Dennis
Ames, Tyler D.
Yim, Christina Y.
Price, Matthew R.
Jimeno, Jose J.
Bergsagel, P. Leif
BLOOD, 2020, 136

← 1 2 3 4 5 →